The Next Frontier: Prolium Advances Novel Autoimmune Therapy PRO-203

NEW YORK, NY – June 22, 2026 – Prolium Bioscience, a clinical-stage company backed by life sciences investor RTW Investments, has taken a significant step forward in the quest to tame severe autoimmune diseases. The company announced today that it has begun treating patients in a pivotal multinational study of its lead candidate, PRO-203, for systemic sclerosis (SSc), a debilitating and often fatal condition. This milestone coincides with the completion of a separate investigator-led study of the same drug in patients with treatment-resistant lupus nephritis (LN).

These developments position PRO-203, a sophisticated biologic known as a T-cell engager, at the forefront of a new wave of therapies designed to reset the immune system with unprecedented precision. The drug’s progress offers a glimmer of hope for patients suffering from diseases where current treatments often fall short, providing only partial relief while carrying significant side effects.

“Dosing the first patient with PRO-203 in systemic sclerosis marks an important milestone for Prolium as we advance our lead program in a disease with profound unmet medical need,” said Scott Requadt, Chief Executive Officer of Prolium Bioscience, in a statement. “T-cell engagers represent the next frontier in autoimmune disease, offering the potential for deep, durable B-cell depletion without the complexity or preconditioning of CAR-T therapies.”

A New Weapon in the Immunological Arsenal

At its core, PRO-203 is designed to solve a complex problem: how to eliminate the body’s rogue B-cells—immune cells that mistakenly produce antibodies against a patient’s own tissues—without causing widespread collateral damage. The drug is a bispecific antibody, a Y-shaped molecule engineered with two different arms. One arm grabs onto CD20, a protein found on the surface of B-cells, while the other arm latches onto CD3, a component of the T-cell receptor. By binding both simultaneously, PRO-203 forms a physical bridge between a patient's own killer T-cells and the destructive B-cells, effectively redirecting the T-cells to attack and destroy their target.

This “T-cell dependent cellular cytotoxicity” is a mechanism borrowed from oncology, where T-cell engagers have revolutionized the treatment of certain cancers. Prolium is now among the pioneers adapting this powerful technology for autoimmunity.

The approach aims to provide a more potent and durable B-cell depletion than existing anti-CD20 monoclonal antibodies like rituximab. While rituximab flags B-cells for destruction by the wider immune system, T-cell engagers directly recruit the immune system’s most effective killers to the job. This offers the potential for a deeper “reset” of the B-cell compartment, which could lead to long-lasting, treatment-free remission—the ultimate goal in chronic autoimmune disease management.

Crucially, PRO-203 is positioned as a more accessible advanced therapy compared to CAR-T cells. While CAR-T therapy, which involves extracting, genetically engineering, and re-infusing a patient's T-cells, has shown remarkable promise in early autoimmunity studies, it is a logistically complex, costly, and high-risk procedure. PRO-203, administered as a subcutaneous injection, is an “off-the-shelf” product that avoids this complexity. “Based on promising data we’ve seen to date, we believe PRO-203 has the potential to achieve sustained remissions in patients with serious autoimmune diseases,” Requadt added.

Addressing Desperate Unmet Needs

The diseases Prolium is targeting are notoriously difficult to treat. Systemic sclerosis, or scleroderma, affects up to 100,000 Americans and is characterized by progressive fibrosis (scarring) of the skin and internal organs like the lungs and heart. There is no cure, and mortality rates are high, with existing treatments focused on managing symptoms and slowing organ damage.

Lupus nephritis, a severe kidney inflammation caused by systemic lupus erythematosus (SLE), affects up to 60% of the approximately 1.4 million people worldwide with lupus. Despite recent therapeutic advances, as many as 30% of patients with LN progress to end-stage renal disease, requiring dialysis or transplantation. For those who are refractory to standard-of-care treatments, the prognosis can be grim.

“The need for truly disease-modifying therapies in both SSc and LN is immense,” one immunologist not involved with the study commented. “We have agents that can blunt the immune response, but achieving deep and lasting remission, especially in refractory patients, remains a major challenge. The concept of using a T-cell engager to achieve a profound B-cell reset is theoretically very powerful and could be a paradigm shift if the safety profile is manageable.”

A Calculated Clinical Path Forward

Prolium’s clinical strategy appears both ambitious and methodical. The newly initiated Phase 1/2 study in SSc (NCT07641634) will enroll up to 24 patients across more than 20 sites in at least five countries. The trial builds on a recently completed Phase 1 study in 20 healthy volunteers, which helped the company establish a safe and appropriate dosing regimen—a critical step for a potent therapy class known for potential side effects like cytokine release syndrome (CRS).

“We’re delighted to have advanced PRO-203 so quickly through what we believe may have been one of the first times a T-cell engager was studied in a SAD study in healthy volunteers,” noted Salim Mujais, MD, Prolium’s Chief Medical Officer. “Having now established the basis for a priming dose regimen for PRO-203, we look forward to exploring its safety and efficacy in SSc as well as other severe autoimmune diseases.”

Meanwhile, the completion of the investigator-sponsored study in five treatment-refractory LN patients in China (NCT07104344) marks another key data catalyst. All patients in that trial have completed their 26-week follow-up, and Prolium has announced that data from both this study and the healthy volunteer trial will be presented at an upcoming medical meeting.

The biotechnology community and patient advocacy groups will be watching closely for this data release. Positive results would not only validate PRO-203’s mechanism in two distinct autoimmune conditions but would also bolster the case for T-cell engagers as a viable and potent new class of medicines for autoimmunity, potentially heralding a new era of treatment for some of the most challenging diseases known to medicine.